TABLE 3.

Histamine-2 receptor antagonists and the risk of hip fracture, by increasing daily dose and cumulative duration of use

	Cumulative Duration (years)
	No use	<1	1–1.9	2–3.9	4–5.9	6–7.9	8–9.9	10
Pills per day		Adjusted Odds Ratios and 95% Confidence Intervals1
0.01–0.74	Reference2	1.17 (1.02–1.35)	1.09 (0.98–1.21)	1.12 (1.02–1.22)	1.03 (0.93–1.14)	1.06 (0.94–1.19)	1.32 (1.14–1.53)	1.29 (1.02–1.62)
0.75–1.49	Reference	1.18 (1.10–1.27)	1.19 (1.06–1.34)	1.14 (1.03–1.27)	1.21 (1.05–1.39)	1.23 (1.04–1.47)	0.95 (0.76–1.19)	1.20 (0.89–1.62)
≥1.5	Reference	1.14 (1.09–1.19)	1.27 (1.12–1.45)	1.34 (1.18–1.51)	1.15 (0.97–1.36)	1.25 (1.01–1.55)	1.10 (0.83–1.46)	1.53 (1.09–2.14)
All doses	Reference	1.11 (1.06–1.15)	1.14 (1.04–1.24)	1.15 (1.06–1.24)	1.10 (0.99–1.22)	1.02 (0.89–1.18)	1.03 (0.86–1.24)	1.31 (1.03–1.66)
Total numbers of cases and controls by duration category3
Cases	20,498	3695	761	924	517	286	169	107
Controls	84,913	13,720	2747	3352	1913	1221	715	333

¹Cases and controls were individually matched for sex, age, duration of membership, first year of membership, and race/ethnicity; models were adjusted for a smoking diagnosis.

²Reference group for all comparisons consists of members with no PPI or H2RA use. PPI user categories could also use H2RAs.

³Number of subjects for each cumulative duration category.